The influence of maintenance therapy of rituximab on the
survival of elderly patients with follicular lymphoma. A
retrospective analysis from the database of the Czech Lymphoma
Study Group

J 2018

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group

BELADA, David, Vit PROCHAZKA, Andrea JANÍKOVÁ, Vit CAMPR, Petra BLAHOVCOVA et. al.

Základní údaje

Originální název

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group

Autoři

BELADA, David (203 Česká republika, garant), Vit PROCHAZKA (203 Česká republika), Andrea JANÍKOVÁ (203 Česká republika, domácí), Vit CAMPR (203 Česká republika), Petra BLAHOVCOVA (203 Česká republika), Robert PYTLIK (203 Česká republika), Alice SYKOROVA (203 Česká republika), Pavel KLENER (203 Česká republika), Katerina BENESOVA (203 Česká republika), Jan PIRNOS (203 Česká republika), Juraj DURAS (203 Česká republika), Heidi MOCIKOVA (203 Česká republika) a Marek TRNENY (203 Česká republika)

Vydání

Leukemia Research, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2018, 0145-2126

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.066

Kód RIV

RIV/00216224:14110/18:00104217

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.leukres.2018.08.019

UT WoS

000446480400007

Klíčová slova anglicky

Follicular lymphoma; Elderly patients; Rituximab; Immunochemotherapy; Maintenance; Survival

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 2. 2019 14:08, Soňa Böhmová

Anotace

V originále

The rituximab maintenance (RM) therapy for follicular lymphoma is effective and clinically well tolerated, however there is limited data regarding this from the elderly segment of the population. This analysis was performed to evaluate the efficacy of RM in elderly patients 65 years of age and older and to assess the influence of the induction therapy with immunochemotherapy (R-CHEMO) on the treatment outcome in a real world setting. A total of 232 consecutive patients treated with first-line R-CHEMO and RM (RM1 group; n = 158) or observation (RM0 group; n = 74) were analyzed. The effect of which induction therapy (R-CHOP vs. R-CVP) and the response of the patients to the first-line therapy were also evaluated. The addition of RM improved the treatment results in elderly patients. The 5- year overall survival rate in patients receiving R-CHEMO + RM1 compared to patients receiving R-CHEMO + RMO, was 83.7% (95% CI 76.1-89%) and 64.3% (95% CI 51.8-74.3%), respectively, p = 0.0012. The induction therapy with R-CHOP was found to be more effective than R-CVP but it is necessary to point out higher age of patients in the R-CVP arm. The 5- year overall survival rate in patients using R-CHOP +/- RM and R-CVP +/- RM was 84.9% (95% CI 77.5-90%), and 65.0% (95% CI 50.1-76.4%), respectively, p = 0.0008. The patients who achieved CR + uCR after having received first-line therapy had better outcomes compared to patients in PR. The 5- year overall survival rate in uCR + CR patients treated with R-CHEMO + RM1 and PR patients treated with R-CHEMO + RM1 was 90.6% and 68.3%, respectively, p = 0.0019. Rituximab maintenance treatment in patients 65 years and older yielded improved survival rates in a real world clinical setting. The R-CHOP regimen seems to be a more effective induction agent than RCVP but the outcome of less intensively treated patients with R-CVP + RM is also acceptable. The achievement of uCR + CR after first-line therapy is associated with a better outcome.

Citovat

BELADA, David, Vit PROCHAZKA, Andrea JANÍKOVÁ, Vit CAMPR, Petra BLAHOVCOVA, Robert PYTLIK, Alice SYKOROVA, Pavel KLENER, Katerina BENESOVA, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA a Marek TRNENY. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. Leukemia Research. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2018, roč. 73, OCT 2018, s. 29-38. ISSN 0145-2126. Dostupné z: https://dx.doi.org/10.1016/j.leukres.2018.08.019.

@article{1455961,
   author = {Belada, David and Prochazka, Vit and Janíková, Andrea and Campr, Vit and Blahovcova, Petra and Pytlik, Robert and Sykorova, Alice and Klener, Pavel and Benesova, Katerina and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Trneny, Marek},
   article_location = {OXFORD},
   article_number = {OCT 2018},
   doi = {http://dx.doi.org/10.1016/j.leukres.2018.08.019},
   keywords = {Follicular lymphoma; Elderly patients; Rituximab; Immunochemotherapy; Maintenance; Survival},
   language = {eng},
   issn = {0145-2126},
   journal = {Leukemia Research},
   title = {The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group},
   volume = {73},
   year = {2018}
}

TY  - JOUR
ID  - 1455961
AU  - Belada, David - Prochazka, Vit - Janíková, Andrea - Campr, Vit - Blahovcova, Petra - Pytlik, Robert - Sykorova, Alice - Klener, Pavel - Benesova, Katerina - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Trneny, Marek
PY  - 2018
TI  - The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group
JF  - Leukemia Research
VL  - 73
IS  - OCT 2018
SP  - 29-38
EP  - 29-38
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 01452126
KW  - Follicular lymphoma
KW  - Elderly patients
KW  - Rituximab
KW  - Immunochemotherapy
KW  - Maintenance
KW  - Survival
N2  - The rituximab maintenance (RM) therapy for follicular lymphoma is effective and clinically well tolerated, however there is limited data regarding this from the elderly segment of the population. This analysis was performed to evaluate the efficacy of RM in elderly patients 65 years of age and older and to assess the influence of the induction therapy with immunochemotherapy (R-CHEMO) on the treatment outcome in a real world setting. A total of 232 consecutive patients treated with first-line R-CHEMO and RM (RM1 group; n = 158) or observation (RM0 group; n = 74) were analyzed. The effect of which induction therapy (R-CHOP vs. R-CVP) and the response of the patients to the first-line therapy were also evaluated. The addition of RM improved the treatment results in elderly patients. The 5- year overall survival rate in patients receiving R-CHEMO + RM1 compared to patients receiving R-CHEMO + RMO, was 83.7% (95% CI 76.1-89%) and 64.3% (95% CI 51.8-74.3%), respectively, p = 0.0012. The induction therapy with R-CHOP was found to be more effective than R-CVP but it is necessary to point out higher age of patients in the R-CVP arm. The 5- year overall survival rate in patients using R-CHOP +/- RM and R-CVP +/- RM was 84.9% (95% CI 77.5-90%), and 65.0% (95% CI 50.1-76.4%), respectively, p = 0.0008. The patients who achieved CR + uCR after having received first-line therapy had better outcomes compared to patients in PR. The 5- year overall survival rate in uCR + CR patients treated with R-CHEMO + RM1 and PR patients treated with R-CHEMO + RM1 was 90.6% and 68.3%, respectively, p = 0.0019. Rituximab maintenance treatment in patients 65 years and older yielded improved survival rates in a real world clinical setting. The R-CHOP regimen seems to be a more effective induction agent than RCVP but the outcome of less intensively treated patients with R-CVP + RM is also acceptable. The achievement of uCR + CR after first-line therapy is associated with a better outcome.
ER  -

BELADA, David, Vit PROCHAZKA, Andrea JANÍKOVÁ, Vit CAMPR, Petra BLAHOVCOVA, Robert PYTLIK, Alice SYKOROVA, Pavel KLENER, Katerina BENESOVA, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA a Marek TRNENY. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. \textit{Leukemia Research}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2018, roč.~73, OCT 2018, s.~29-38. ISSN~0145-2126. Dostupné z: https://dx.doi.org/10.1016/j.leukres.2018.08.019.

Podrobný výpis o publikaci